Clavis Pharma appoints chief business officer
Nicholas Adams takes the role at Norwegian firm
For the past 12 years, Adams worked for the UK cancer company, Antisoma plc, the majority of the time as vice president business development and a member of the senior management team.
Prior to this, he spent 11 years in various positions at Ciba-Geigy (now Novartis), Eisai and Covance.
Olav Hellebø, ceo of Clavis Pharma, said Adams brings to the company considerable experience in business development, particularly in building partnerships with leading pharmaceutical companies, and with a strong focus in oncology.
You may also like
Regulatory
MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results
The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Manufacturing
Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours
The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Research & Development
AlzeCure Pharma publishes response letter clarifying Alzstatin’s distinct mechanism in Alzheimer’s treatment
AlzeCure Pharma and leading academic collaborators have published a response in JPET addressing recent commentary on Alzstatin’s γ-secretase modulation data, reaffirming the promise of lead candidate ACD680 in Alzheimer’s therapy